The spontaneous CD8+ T-cell response to HLA-A2-restricted NY-ESO-1b peptide in hepatocellular carcinoma patients

Clinical Cancer Research

Volumn 10, Issue 20, 2004, Pages 6946-6955

  Shang, Xiao Ying ^a   Chen, Hong Song ^a   Zhang, Hua Gang ^a   Pang, Xue Wen ^a   Qiao, Huan ^a   Peng, Ji Run ^a   Qin, Li Ling ^b   Fei, Ran ^a   Mei, Ming Hui ^b   Leng, Xi Sheng ^a   Gnjatic, Sacha ^c   Ritter, Gerd ^c   Simpson, Andrew J G ^c   Old, Lloyd J ^c   Chen, Wei Feng ^a  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b GUILIN MEDICAL UNIVERSITY   (China)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; CTP11 ANTIGEN; GAMMA INTERFERON; GRANZYME B; HLA A2 ANTIGEN; MELANOMA ANTIGEN; NY ESO 1B PEPTIDE; PEPTIDE; SCP 1 ANTIGEN; SSX ANTIGEN; T LYMPHOCYTE ANTIGEN; TETRAMER; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIBODY RESPONSE; ANTIGEN EXPRESSION; ANTIGEN RECOGNITION; ARTICLE; CANCER IMMUNOTHERAPY; CANCER STAGING; CELL STRAIN HEPG2; CONTROLLED STUDY; CYTOKINE RELEASE; EFFECTOR CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; ENZYME RELEASE; FEMALE; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; IN VITRO STUDY; LIVER CELL CARCINOMA; LYMPHOCYTE FUNCTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN FAMILY; T LYMPHOCYTE;

ADULT; AGED; ANTIBODY FORMATION; ANTIGENS, NEOPLASM; CANCER VACCINES; CARCINOMA, HEPATOCELLULAR; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; FLOW CYTOMETRY; GRANZYMES; HLA-A2 ANTIGEN; HUMANS; IMMUNOASSAY; IMMUNOTHERAPY; INTERFERON TYPE II; LIVER NEOPLASMS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; PEPTIDE FRAGMENTS; SERINE ENDOPEPTIDASES;

EID: 6044242149     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-0502     Document Type: Article

References (26)

1. Old LJ. Tumor immunology: the first century. Curr Opin Immunol 1992;4:603-7.
2. Rosenberg SA. Progress in human tumour immunology and immunotherapy. Nature (Lond) 2001;411:380-4.
3. Jager D, Jager E, Knuth A. Immune responses to tumour antigens: implications for antigen specific immunotherapy of cancer. J Clin Pathol 2001;54:669-74.
4. Scanlan MJ, Gordon CM, Williamson B, et al. Identification of cancer/testis genes by database mining and mRNA expression analysis. Int J Cancer 2002;98:485-92.
5. Jager E, Gnjatic S, Nagata Y, et al. Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers. Proc Natl Acad Sci USA 2000;97:12198-203.
6. Stocken E, Jager E, Chen YT, et al. A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. J Exp Med 1998;187:1349-54.
7. Miyamoto A, Fujiwara Y, Sakon M, et al. Development of a multiple-marker RT-PCR assay for detection of micrometastases of hepatocellular carcinoma. Dig Dis Sci 2000;45:1376-82.
8. Kobayashi Y, Higashi T, Nouso K, et al. Expression of MAGE, GAGE and BAGE genes in human liver diseases: utility as molecular markers for hepatocellular carcinoma. J Hepatol 2000;32:612-7.
9. Chen CH, Huang GT, Lee HS, et al. High frequency of expression of MAGE genes in human hepatocellular carcinoma. Liver 1999;19:110-4.
10. Kariyama K, Higashi T, Kobayashi Y, et al. Expression of MAGE-1 and -3 genes and gene products in human hepatocellular carcinoma. Br J Cancer 1999;81:1080-7.
11. Chen H, Cai S, Wang Y, et al. Expression of the MAGE-1 gene in human hepatocellular carcinomas. Chin Med J (Engl Ed) 2000;113:1112-8.
12. Chen CH, Chen GJ, Lee HS, et al. Expressions of cancer-testis antigens in human hepatocellular carcinomas. Cancer Lett 2001;164:189-95.
13. Dong XY, Su YR, Qian XP, et al. Identification of two novel CT antigens and their capacity to elicit antibody response in hepatocellular carcinoma patients. Br J Cancer 2003;89:291-7.
14. Zerbini A, Pilli M, Soliani P, et al. Ex vivo characterization of tumor-derived melanoma antigen encoding gene-specific CD8+ cells in patients with hepatocellular carcinoma. J Hepatol 2004;40:102-9.
15. Ladhams A, Schmidt C, Sing G, et al. Treatment of non-resectable hepatocellular carcinoma with autologous tumor-pulsed dendritic cells. J Gastroenterol Hepatol 2002;17:889-96.
16. Zhang HG, Pang XW, Shang XY, Xing Q, Chen WF. Functional supertype of HLA-A2 in the presentation of Flu matrix p58-66 to induce CD8+ T-cell response in a Northern Chinese population. Tissue Antigens 2003;62:285-95.
17. Jager E, Nagata Y, Gnjatic S, et al. Monitoring CD8 T cell responses to NY-ESO-1: correlation of humoral and cellular immune responses. Proc Natl Acad Sci USA 2000;97:4760-5.
18. Chen YT, Scanlan MJ, Sahin U, et al. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci USA 1997;94:1914-8.
19. 51Cr-release assay for monitoring cell-mediated cytotoxicity. J Transl Med 2003;1:14.
20. Salio M, Shepherd D, Dunbar PR, et al. Mature dendritic cells prime functionally superior melan-A-specific CD8+ lymphocytes as compared with nonprofessional APC. J Immunol 2001;167:1188-97.
21. Barry M, Bleackley RC. Cytotoxic T lymphocytes: all roads lead to death. Nat Rev Immunol 2002;2:401-9.
22. Valmori D, Dutoit V, Lienard D, et al. Naturally occurring human lymphocyte antigen-A2 restricted CD8+ T-cell response to the cancer testis antigen NY-ESO-1 in melanoma patients. Cancer Res 2000;60:4499-506.
23. Fleischhauer K, Tanzarella S, Russo V, et al. Functional heterogeneity of HLA-A*02 subtypes revealed by presentation of a MAGE-3-encoded peptide to cytotoxic T cell clones. J Immunol 1997;159:2513-21.
24. Mou DC, Cai SL, Peng JR, et al. Evaluation of MAGE-1 and MAGE-3 as tumour-specific markers to detect blood dissemination of hepatocellular carcinoma cells. Br J Cancer 2002;86:110-6.
25. Gnjatic S, Atanackovic D, Jager E, et al. Survey of naturally occurring CD4+ T cell responses against NY-ESO-1 in cancer patients: correlation with antibody responses. Proc Natl Acad Sci USA 2003;100:8862-7.
26. Jager E, Stocken E, Zidianakis Z, et al. Humoral immune responses of cancer patients against "Cancer-Testis" antigen NY-ESO-1: correlation with clinical events. Int J Cancer 1999;84:506-10.